The pathogenicity of anti-TIF1-γ is plausible, as supported by the finding of TIF1-γ overexpression in endometrial cancer cells in patients with cancer-associated DM with anti-TIF1-γ autoantibodies [104]. The gene discussed is TRIM33; the disease is cancer.